{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:08:08Z","timestamp":1792195688148,"version":"4.4.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.1001\/jamaneurol.2019.4113","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T15:40:48Z","timestamp":1575301248000},"page":"300","source":"Crossref","is-referenced-by-count":242,"title":["Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens"],"prefix":"10.1001","volume":"77","author":[{"given":"Rima","family":"Nabbout","sequence":"first","affiliation":[{"name":"H\u00f4pital Universitaire Necker\u2013Enfants Malades, Service de Neurologie P\u00e9diatrique Centre de R\u00e9f\u00e9rence \u00c9pilepsies Rares, Imagine Institute, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale,  Unite Mixt\u00e9 de Recherche 1163, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Mistry","sequence":"additional","affiliation":[{"name":"Zogenix, Inc, Emeryville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Zuberi","sequence":"additional","affiliation":[{"name":"Paediatric Neurosciences Research Group, Royal Hospital for Children Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Villeneuve","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Marseille, Department of Pediatric Neurology, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[{"name":"Hospital Ruber Internacional, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Sanchez-Carpintero","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Unit, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Stephani","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics, Christian-Albrechts-University, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Laux","sequence":"additional","affiliation":[{"name":"Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Wirrell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Knupp","sequence":"additional","affiliation":[{"name":"University of Colorado, Children\u2019s Hospital Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chiron","sequence":"additional","affiliation":[{"name":"Pediatric Neurology, Necker-Enfants Malades Hospital, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale  Unite 1141, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Farfel","sequence":"additional","affiliation":[{"name":"Zogenix, Inc, Emeryville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Galer","sequence":"additional","affiliation":[{"name":"Zogenix, Inc, Emeryville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Morrison","sequence":"additional","affiliation":[{"name":"Zogenix, Inc, Emeryville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[{"name":"Zogenix, Inc, Emeryville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Zogenix, Inc, Emeryville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[{"name":"Robert Debr\u00e9 University Hospital, Universit\u00e9 de Paris, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unite 1141, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the FAiRE, DS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"noi190095r1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel.","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"5","key":"noi190095r2","doi-asserted-by":"publisher","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","article-title":"Incidence of Dravet syndrome in a US population.","volume":"136","author":"Wu","year":"2015","journal-title":"Pediatrics"},{"key":"noi190095r3","first-page":"71","article-title":"Severe myoclonic epilepsy in infancy: Dravet syndrome.","volume":"95","author":"Dravet","year":"2005","journal-title":"Adv Neurol"},{"issue":"3","key":"noi190095r4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jmg.2008.062323","article-title":"Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients.","volume":"46","author":"Depienne","year":"2009","journal-title":"J Med Genet"},{"key":"noi190095r5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1528-1167.2011.03012.x","article-title":"Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief.","volume":"52","author":"Skluzacek","year":"2011","journal-title":"Epilepsia"},{"key":"noi190095r6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","article-title":"Mortality in Dravet syndrome.","volume":"128","author":"Cooper","year":"2016","journal-title":"Epilepsy Res"},{"issue":"3","key":"noi190095r7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5698\/1535-7511.17.3.180","article-title":"Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society.","volume":"17","author":"Harden","year":"2017","journal-title":"Epilepsy Curr"},{"key":"noi190095r8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","article-title":"The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.","volume":"44","author":"Aras","year":"2015","journal-title":"Epilepsy Behav"},{"key":"noi190095r9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eplepsyres.2016.05.012","article-title":"Patients with Dravet syndrome in the era of stiripentol: a French cohort cross-sectional study.","volume":"125","author":"De Liso","year":"2016","journal-title":"Epilepsy Res"},{"issue":"17","key":"noi190095r10","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","article-title":"Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.","volume":"88","author":"Harden","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"noi190095r11","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/epi.14536","article-title":"Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?","volume":"59","author":"Chiron","year":"2018","journal-title":"Epilepsia"},{"key":"noi190095r12","article-title":"ZX008 (fenfluramine HCl oral solution) in Dravet syndrome: results of a phase 3, randomized, double-blind, placebo-controlled trial.","author":"Lagae","journal-title":"Lancet"},{"issue":"1","key":"noi190095r15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5414\/CP203276","article-title":"A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects.","volume":"57","author":"Boyd","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"noi190095r16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.yebeh.2003.08.012","article-title":"Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients.","volume":"4","author":"Sabaz","year":"2003","journal-title":"Epilepsy Behav"},{"issue":"8","key":"noi190095r17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"issue":"12","key":"noi190095r18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11940-018-0537-y","article-title":"Current treatment strategies and future treatment options for Dravet syndrome.","volume":"20","author":"Ziobro","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"noi190095r19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/ODRR","article-title":"Stiripentol for the treatment of Dravet syndrome.","volume":"4","author":"Chiron","year":"2014","journal-title":"Orphan Drugs Res Rev"},{"issue":"9242","key":"noi190095r20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"issue":"21","key":"noi190095r22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"noi190095r23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.echo.2015.03.012","article-title":"Valvular regurgitation using portable echocardiography in a healthy student population: implications for rheumatic heart disease screening.","volume":"28","author":"Webb","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"noi190095r25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension.","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"key":"noi190095r26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1741-7015-6-34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.","volume":"6","author":"Dahl","year":"2008","journal-title":"BMC Med"},{"key":"noi190095r27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2261-3-5","article-title":"Risk of valvular heart disease associated with use of fenfluramine.","volume":"3","author":"Hopkins","year":"2003","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"noi190095r28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.","volume":"339","author":"Jick","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"noi190095r29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1378\/chest.117.3.870","article-title":"Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.","volume":"117","author":"Rich","year":"2000","journal-title":"Chest"},{"issue":"2","key":"noi190095r30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ene.2017.24.issue-2","article-title":"Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.","volume":"24","author":"Schoonjans","year":"2017","journal-title":"Eur J Neurol"},{"issue":"10","key":"noi190095r32","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","article-title":"Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.","volume":"33","author":"Schoonjans","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"noi190095r33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/epi.2012.53.issue-7","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome.","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"issue":"7","key":"noi190095r34","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1111\/epi.13407","article-title":"Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine.","volume":"57","author":"Ceulemans","year":"2016","journal-title":"Epilepsia"},{"key":"noi190095r13","author":"Rubino","year":"2017"},{"key":"noi190095r31","author":"Lai","year":"2018"},{"key":"noi190095r14","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. E6(R2) Good clinical practice: integrated addendum to ICH E6(R1) guidance for industry. https:\/\/www.fda.gov\/media\/93884\/download. Published March 2018. Accessed October 28, 2019."},{"key":"noi190095r21","unstructured":"European Medicines Agency. Diacomit: EPAR\u2014scientific discussion. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/diacomit-epar-scientific-discussion_en.pdf. Published January 29, 2009. Accessed February 28, 2019."},{"key":"noi190095r24","unstructured":"BachorikL. FDA announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen). https:\/\/wayback.archive-it.org\/7993\/20170723090512\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm179871.htm. Published 1997. Accessed May 29, 2018."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2756124\/jamaneurology_nabbout_2019_oi_190095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T11:00:59Z","timestamp":1583751659000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2756124"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.4113","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}